Shares of Veracyte cratered 17.2% to $43.50 after the cancer diagnostics company reported Q3 results on November 4 that, on paper, looked solid — but came packaged with a sobering trim to full-year expectations. The company grew total revenue to $151.8 million and testing revenue to $146.4 million, both representing 15% year-over-year growth.
Diluted earnings per share came in at $0.38, up $0.14 from a year ago. The beat, however, is being overshadowed by what the company said next.
• The Guidance Cut That Spooked the Street
Veracyte narrowed its full-year 2026 revenue outlook to $590–$593 million, down from a prior range of $590–$596 million. More importantly, testing revenue guidance dropped to $571–$573 million — representing 16% growth — compared to the prior $576–$582 million range. That $5–$9 million haircut to the testing revenue ceiling signals that Veracyte's highest-value product line, its prostate cancer genomic test, is not growing as fast as management expected. For a stock that traded at roughly 35 times earnings before this report, even a modest growth deceleration hits hard.
• The Prostate Test Volume Problem Keeps Getting Worse This is the second consecutive quarter Veracyte has trimmed its prostate test volume projections. In Q2, the company cut expected volume by roughly 1,000 tests, blaming an industry guideline change that removed genomic testing from active-surveillance recommendations for low-risk patients.
Analysts have pressed management on whether AI-based testing tools are taking share , and the recurring volume misses give that question more weight. With prostate testing generating over 60% of Veracyte's total revenue, any sustained slowdown threatens the entire growth narrative.
• A $100 Million Buyback Can't Paper Over a Growth Question
The board authorized a $100 million share repurchase program alongside the results. Buybacks signal management's confidence in the stock price, but they also signal that the company may lack higher-return places to deploy capital. Veracyte generated $121.3 million in operating cash flow through the first nine months of 2026 , so it can afford the program — but investors clearly wanted volume acceleration, not financial engineering.
• New Products Haven't Earned Their Keep Yet
Product revenue rose 40% to $4.6 million, driven by adoption of its breast cancer test following positive trial data at ASCO. But recently launched tests are contributing minimal revenue to the 2026 outlook. Until new products meaningfully diversify the revenue base, Veracyte's stock will live and die by prostate test volumes — and right now, those volumes are going the wrong direction.